He succeeds Dr. Axel Steiger-Bagel, who takes over on November 1 as Senior Bayer Representative for the Benelux countries, based in Diegem, near Brussels.
Lutz – like his predecessor – will be a member of the Board of Management of Bayer MaterialScience and that subgroup's Executive Committee. He will be responsible for all finance-related matters of MaterialScience, which it is planned to float on the stock market as a separate company in 12 to 18 months' time. His responsibilities on the Executive Committee will also include administration and services along with the Europe, Africa and Middle East regions (EMEA / EEMEA).
"I would like to thank Dr. Axel Steiger-Bagel for his more than seven years of dedicated service on the Executive Committee of Bayer MaterialScience. He deserves much of the credit for the company's good and efficient development over recent years," said Werner Baumann, member of the Board of Management of Bayer AG and Chairman of the Supervisory Board of Bayer MaterialScience. "At the same time I am pleased at the appointment of such an acknowledged financial expert as Frank Lutz. He will be able to apply his wide-ranging expertise to MaterialScience's preparations for its stock market flotation."
Patrick Thomas, Chief Executive Officer of Bayer MaterialScience said: “Dr. Steiger-Bagel has made significant contributions to MaterialScience throughout his time with us and we wish him every success in his future Bayer career. At the same time, I am delighted to welcome Frank Lutz to the Executive Committee and I am very much looking forward to working with him.”
Lutz studied economics and business administration at the university of St. Gallen, Switzerland, and began his career in 1995 at Goldman Sachs. After a period working for Deutsche Bank, he was appointed Senior Vice President for Finance at MAN. Three years later he became Chief Financial Officer of MAN SE, Munich, Germany. On May 1, 2013, Lutz was appointed to the Coordination Council of the Aldi Süd group of companies, where as CFO he bore responsibility for the retailer's finances.
Dr. Axel Steiger-Bagel joined Bayer AG's legal department in 1999, having served for two years in Germany and the United States with a well-known law firm. At the beginning of 2002, Steiger-Bagel transferred to the Corporate Center to work as an assistant to the Board of Management. Then in 2006 he was appointed Managing Director, Senior Bayer Representative and Bayer HealthCare Senior Country Representative in Turkey. Since March 2007, Steiger-Bagel has been a member of the Board of Management of Bayer MaterialScience AG with responsibility for administration and services (including Controlling, Organization & IT, Law & Patents, Supply Chain Centers etc.) as well as the Europe, Africa and Middle East regions (EMEA / EEMEA).
About Bayer MaterialScience:
With 2013 sales of EUR 11.2 billion, Bayer MaterialScience is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. At the end of 2013, Bayer MaterialScience had 30 production sites and employed approximately 14,300 people around the globe. Bayer MaterialScience is a Bayer Group company.
This news release is available for download from the Bayer MaterialScience press server at www.press.bayerbms.com.
Note to editors:
Print-quality photos can be downloaded from our website at www.news.bayer.com
Find more information at www.materialscience.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.